G17DT: An antigastrin immunogen for the treatment of gastrointestinal malignancy

Expert Opinion on Biological Therapy

Volumn 7, Issue 3, 2007, Pages 397-404

  Gilliam, A D ^b   Watson, S A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

Angiogenesis; Apoptosis; Colorectal cancer; G17DT; Gastric cancer; Gastrin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CISPLATIN; EXATECAN; FLUOROURACIL; G 17DT; GASTRAZOLE; GASTRIMMUNE; GASTRIN 17; GASTRIN 17 ANTIBODY; GEMCITABINE; HORMONE ANTIBODY; IMMUNOLOGIC AGENT; IRINOTECAN; JB 95008; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; HUMAN; IMMUNE RESPONSE; INJECTION SITE ABSCESS; MONOTHERAPY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PASSIVE IMMUNIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH ACID SECRETION; STOMACH CANCER; TREATMENT OUTCOME; VOMITING;

ANTIBODY FORMATION; CANCER VACCINES; CLINICAL TRIALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRINS; GASTROINTESTINAL NEOPLASMS; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 33847699242     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.3.397     Document Type: Review

References (26)

1. WATSON SA, GRABOWSKA AM, EL-ZAATARI M, TAKHAR A: Gastrin - active participant or bystander in gastric carcinogenesis? Nat. Rev. Cancer (2006) 6:936-946.
2. MIYAZAKI Y, SHINOMURA Y, TSUTSUI S et al.: Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology (1999) 116:78-89.
3. VARRO A, NOBLE PJ, WROBLEWSKI LE, BISHOP L, DOCKRAY GJ: Gastrin-cholecystokinin(B) receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor. Gut (2002) 50:827-833.
4. NOBLE PJ, WILDE G, WHITE MR et al.: Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am. J. Physiol. Gastrointest. Liver Physiol. (2003) 284:G75-G84.
5. FUKUI H, KINOSHITA Y, MAEKAWA T et al.: Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology (1998) 115:1483-1493.
6. GUO YS, CHENG JZ, JIN GF et al.: Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J. Biol. Chem. (2002) 277:48755-48763.
7. KERMORGANT S, LEHY T: Glycine-extended gastrin promotes the invasiveness of human colon cancer cells, Biochem. Biophys. Res. Commun. (2001) 285:136-141.
8. HARRIS JC, GILLIAM AD, MCKENZIE AJ et al.: The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res. (2004) 64:5624-5631.
9. CARMICHAEL J: Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion (1997) 58:503-507.
10. BURRIS HA 3RD, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
11. LOUVET C, LABIANCA R, HAMMEL P et al.: GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic andenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 4008.
12. O'REILLY M, ABOU-ALFA GK, LETOURNEAU R et al.: A randomized Phase III trial of DX-8951f (exatecan mesylate;DX) and gemcitabine (GEM) versus gemcitabine alone in advanced pancreatic cancer (APC). Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 4006.
13. RICHARDS DA, KINDLER HL, OETTLE H et al.: A randomized Phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 4007.
14. CHAU I, CUNNINGHAM D, RUSSELL C et al.: Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer (2006) 94:1107-1115.
15. WATSON SA, GILLIAM AD: G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin. Biol. Ther. (2001) 1:309-317.
16. GILLIAM AD, HENWOOD M, WATSON SA et al.: G17DT - A study to detemine the safety, tolerance and antibody response in patients with advanced pancreatic carcinoma. J. Clin. Oncol. (2001) 120:1350.
17. SMITH JP, VERDERAME MF, ZAGON IS: Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett. (1999) 135:107-112.
18. GILLIAM AD, TOPUZOV EG, GARIN AM et al.: Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 2511.
19. TAKHAR AS, GILLIAM AD, WATSON SA et al.: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur. J. Surg. Oncol. (2006) 32:197-200.
20. BRETT BT, SMITH SC, BOUVIER CV et al.: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. (2002) 20:4225-4231.
21. SMITH AM, WATSON SA: Gastrin and colorectal cancer. Aliment. Pharmacol. Ther. (2000) 14:1231-1247.
22. ROCHA LIMA CM, BUCK RD, MEYER K et al.: A multi-centre Phase II study of irinotecan in comabination with G17DT immunogen in subjects with metastatic colorectal adenocarcinoma (CRC) refractory to previous irinotecan-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 3573.
23. MICHAELI D, HECHT JR, OORTGIESEN M et al.: Final data of the multicener Phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in chemonaive patients with locally recurrent or metastatic gastric and gastroesophageal cancer. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 4048.
24. BROOME P, BUCK RD, MICHAELI D: Immune response to gastrin-17 is an independent covariate in determination of survival in colorectal, gastric and pancreatic cancers. Proc. Am. Soc. Clin. Oncol. (2004) 22(Suppl.):Abstract 4073.
25. AJANI JA, RANDOLPH HECHT J, HO L et al.: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer (2006) 106(9):1908-1916.
26. SHAPIRO J, MARSHALL J, KARASEK P et al.: G17DT+ gemcitabine [gem] versus placebo+gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomised, double-blind, multinational, multicenter study. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4012.